29
Enhancing Host-anti-tumor Response by Preventing Thrombin Cleavage of Osteopontin
Stanford SPARK Program
Antibody
Oncology
Hit To Lead or Lead Optimization
Modulation of macrophages by inhibition of thrombin cleavage of osteopontin (OPN) prevents suppression of host-anti-tumor immune response and up-regulates tissue repair instead of fibrotic reactions. We have identified a monoclonal antibody that prevents
thrombin cleavage of OPN and shows efficacy in in vivo models.
Unmet Need
Despite significant survival improvements due to immunotherapy and targeted therapy, prognosis for patients with many cancer types such as unresectable or metastatic malignant melanoma remains poor.
Approach
Our therapeutic will prevent thrombin-cleavage of OPN thereby enhancing the host’s anti-tumor immune response via modulation of tumor-associated macrophages resulting in an effective adjunctive therapy for cancer treatment. It may also block pathological fibrosis
in various fibrotic diseases.
John Morser
PCT-US2020-045466 (2020.08.07)
Patent Family: PCT, US, EP, JP, CN, KR, CA, AU
Peraramelli et al. Thrombin cleavage of osteopontin initiates osteopontin's tumor-promoting activity. J Thromb Haemost. 2022 May;20(5):1256-1270. PMID: 35108449
